✦ LIBER ✦

Workgroup #3: Monitoring effects of treatment for cancer and for benign prostatic hyperplasia

✍ Scribed by George W. Jones; Robert A. Smith; John D. Batjer; David G. Bostwick; Benjamin W. Corn; Harry A. Guess; M'Liss A. Hudson; John Kabalin; Mark S. Soloway

Publisher: John Wiley and Sons
Year: 1993
Tongue: English
Weight: 223 KB
Volume: 71
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19930415)71:8<2681::aid-cncr2820710841>3.0.co;2-a

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Panel VIII: Surgical treatment for benig

Panel VIII: Surgical treatment for benign prostatic hyperplasia

✍ Charles Brendler; Peter Schlegel; Joseph Dowd; Roger Kirby; Filiberto Zattoni 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 239 KB 👁 1 views

Indications for treatment of benign pros

Indications for treatment of benign prostatic hyperplasia. The American Urological Association Study

✍ Abraham T. K. Cockett; Michael J. Barry; H. Logan Holtgrewe; Stephen Sihelnick; 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 326 KB 👁 1 views

Panel VII: Scope of the problem. Indicat

Panel VII: Scope of the problem. Indications for treatment and assessment of benign prostatic hyperplasia and its relationship to cancer

✍ Winston Mebust; David Bostzvick; John Grayhack; Logan Holtgrewe; John Wasson; Ro 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 183 KB 👁 2 views

Estrogen treatment for cancer of the pro

Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo

✍ John C. Bailar III; David P. Byar; The veterans administration cooperative urolo 📂 Article 📅 1970 🏛 John Wiley and Sons 🌐 English ⚖ 365 KB 👁 1 views

Effects of long-term treatment withSeren

Effects of long-term treatment withSerenoa repens (Permixon®) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia

✍ Di Silverio, F.; Monti, S.; Sciarra, A.; Varasano, P.A.; Martini, C.; Lanzara, S 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 191 KB 👁 1 views

## Background: The n-hexane lipido-sterol extract of serenoa repens (lsesr, permixon, pierre fabre medicament, castres, france), a phytotherapeutic agent used in the treatment of benign prostatic hyperplasia (bph), has a multisite mechanism of action including inhibition of types 1 and 2 5alpha-red

CAG repeat within the androgen receptor

CAG repeat within the androgen receptor gene and incidence of surgery for benign prostatic hyperplasia in U.S. physicians

✍ Giovannucci, Edward; Stampfer, Meir J.; Chan, Andrew; Krithivas, Krishna; Gann, 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 1 views

BACKGROUND. CAG repeat length in exon 1 of the androgen receptor (AR) gene correlates inversely with transcriptional transactivation activity of the AR. Men with shorter AR CAG repeat lengths are at higher risk of prostate cancer. Because benign prostatic hyperplasia (BPH) is an androgen-dependent c